WO2008121127A3 - Methods of use of polycomb homologue mel-18 - Google Patents

Methods of use of polycomb homologue mel-18 Download PDF

Info

Publication number
WO2008121127A3
WO2008121127A3 PCT/US2007/021966 US2007021966W WO2008121127A3 WO 2008121127 A3 WO2008121127 A3 WO 2008121127A3 US 2007021966 W US2007021966 W US 2007021966W WO 2008121127 A3 WO2008121127 A3 WO 2008121127A3
Authority
WO
WIPO (PCT)
Prior art keywords
mel
polycomb
homologue
methods
provides
Prior art date
Application number
PCT/US2007/021966
Other languages
French (fr)
Other versions
WO2008121127A2 (en
Inventor
John Benson
Dmitri Wiederschain
Original Assignee
Novartis Ag
John Benson
Dmitri Wiederschain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, John Benson, Dmitri Wiederschain filed Critical Novartis Ag
Publication of WO2008121127A2 publication Critical patent/WO2008121127A2/en
Publication of WO2008121127A3 publication Critical patent/WO2008121127A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides antagonists of polycomb homologues such as Mel-18 and uses thereof. The invention specifically provides Mel-18 specific RNAi constructs for use in inhibiting proliferative diseases, including especially cancer.
PCT/US2007/021966 2007-03-29 2007-10-15 Methods of use of polycomb homologue mel-18 WO2008121127A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82978707P 2007-03-29 2007-03-29
US60/829,787 2007-03-29

Publications (2)

Publication Number Publication Date
WO2008121127A2 WO2008121127A2 (en) 2008-10-09
WO2008121127A3 true WO2008121127A3 (en) 2008-12-04

Family

ID=39272917

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/021966 WO2008121127A2 (en) 2007-03-29 2007-10-15 Methods of use of polycomb homologue mel-18

Country Status (1)

Country Link
WO (1) WO2008121127A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052392A2 (en) * 2002-12-11 2004-06-24 The University Of Birmingham Cancer immunotherapy using polycomb proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052392A2 (en) * 2002-12-11 2004-06-24 The University Of Birmingham Cancer immunotherapy using polycomb proteins

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
CAPDEVILLE R ET AL: "GLIVEC (STI571,IMATINIB), A RATIONALLY DEVELOPED, TARGETED ANTICANCER DRUG", NATURE REVIEWS. DRUG DISCOVERY, NATURE PUBLISHING GROUP, BASINGSTOKE, GB, vol. 1, no. 7, 1 July 2002 (2002-07-01), pages 493 - 502, XP009043110, ISSN: 1474-1784 *
DATTA SONAL ET AL: "Bmi-1 cooperates with H-ras to transform human mammary epithelial cells via Dysregulation of multiple growth-regulatory pathways", CANCER RESEARCH, vol. 67, no. 21, November 2007 (2007-11-01), pages 10286 - 10295, XP002495430, ISSN: 0008-5472 *
GUO WEI-JIAN ET AL: "Mel-18 acts as a tumor suppressor by repressing Bmi-1 expression and down-regulating Akt activity in breast cancer cells", CANCER RESEARCH, vol. 67, no. 11, June 2007 (2007-06-01), pages 5083 - 5089, XP002495429, ISSN: 0008-5472 *
GUO WEI-JIAN ET AL: "Mel-18, a polycomb group protein, regulates cell proliferation and senescence via transcriptional repression of Bmi-1 and c-Myc oncoproteins", MOLECULAR BIOLOGY OF THE CELL, vol. 18, no. 2, February 2007 (2007-02-01), pages 536 - 546, XP002476603, ISSN: 1059-1524 *
HAMER K M ET AL: "A PANEL OF MONOCLONAL ANTIBODIES AGAINST HUMAN POLYCOMB GROUP PROTEINS", HYBRIDOMA AND HYBRIDOMICS, MARY ANN LIEBERT, NEW YORK, NY, US, vol. 21, no. 4, August 2002 (2002-08-01), pages 245 - 252, XP008015767, ISSN: 1536-8599 *
JACOBS J J L ET AL: "Polycomb repression: from cellular memory to cellular proliferation and cancer", BBA - REVIEWS ON CANCER, ELSEVIER SCIENCE BV, AMSTERDAM, NL, vol. 1602, no. 2, 21 June 2002 (2002-06-21), pages 151 - 161, XP004356807, ISSN: 0304-419X *
KANNO M ET AL: "MEL-18, A POLYCOMB GROUP-RELATED MAMMALIAN GENE, ENCODES A TRANSCRIPTIONAL NEGATIVE REGULATOR WITH TUMOR SUPPRESSIVE ACTIVITY", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 14, no. 22, 1995, pages 5672 - 5678, XP000929505, ISSN: 0261-4189 *
MIYAZAKI MASAKI ET AL: "Polycomb group gene mel-18 regulates early T progenitor expansion by maintaining the expression of Hes-1, a target of the notch pathway", JOURNAL OF IMMUNOLOGY, vol. 174, no. 5, 1 March 2005 (2005-03-01), pages 2507 - 2516, XP002476604, ISSN: 0022-1767 *
NELSON J B ET AL: "ENDOTHELIN-1 PRODUCTION AND DECREASED ENDOTHELIN B RECEPTOR EXPRESSION IN ADVANCED PROSTATE CANCER", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 56, no. 4, 15 February 1996 (1996-02-15), pages 663 - 668, XP001026084, ISSN: 0008-5472 *
NELSON JOEL ET AL: "The endothelin axis: Emerging role in cancer.", NATURE REVIEWS CANCER, vol. 3, no. 2, February 2003 (2003-02-01), pages 110 - 116, XP002495431, ISSN: 1474-175X *
PICKERING ET AL: "Elevated salivary endothelin levels in oral cancer patients-A pilot study", ORAL ONCOLOGY, ELSEVIER SCIENCE, OXFORD, GB, vol. 43, no. 1, 30 January 2007 (2007-01-30), pages 37 - 41, XP005866059, ISSN: 1368-8375 *
SILVA JAVIER ET AL: "Implication of polycomb members Bmi-1, Mel-18, and Hpc-2 in the regulation of p16INK4a, p14ARF, h-TERT, and c-Myc expression in primary breast carcinomas.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH 1 DEC 2006, vol. 12, no. 23, 1 December 2006 (2006-12-01), pages 6929 - 6936, XP002476602, ISSN: 1078-0432 *
WIEDERSCHAIN DMITRI ET AL: "Contribution of polycomb homologues Bmi-1 and Mel-18 to medulloblastoma pathogenesis", MOLECULAR AND CELLULAR BIOLOGY, vol. 27, no. 13, July 2007 (2007-07-01), pages 4968 - 4979, XP002476605, ISSN: 0270-7306 *

Also Published As

Publication number Publication date
WO2008121127A2 (en) 2008-10-09

Similar Documents

Publication Publication Date Title
MX2009008347A (en) Oxabicycloheptanes and oxabicycloheptenes, their preparation and use.
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2008079988A3 (en) Quinazolines for pdk1 inhibition
WO2008094708A3 (en) Activin-actriia antagonists and uses for treating or preventing breast cancer
WO2010011296A3 (en) Deacetylase inhibitors and uses thereof
UA104459C2 (en) Anti-fgfr3 antibodies and methods using same
WO2006083971A3 (en) Dr5 antibodies and uses thereof
WO2006107451A3 (en) Honokiol derivatives for the treatment of proliferative disorders
TN2011000463A1 (en) Composition and methods for increasing muscle growth
WO2012076293A9 (en) Formulations comprising polysiloxanes having nitrogen-containing groups
WO2012058592A3 (en) Non-antagonistic egfr-binding molecules and immunoconjugates thereof
EP4349868A3 (en) Humanized and chimeric monoclonal antibodies to cd47
WO2011032169A3 (en) Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
WO2010132370A8 (en) Soluble trem-1 family peptides and methods of use
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
WO2009158374A3 (en) Inhibitors of akt activity
WO2011160052A3 (en) Methods and compositions for sequence specific rna endonucleases
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use
TW200738751A (en) Anti-EphrinB2 antibodies and methods using same
WO2008112290A3 (en) Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer
WO2010141956A3 (en) Methods and compositions for the treatment of cancer
WO2009152167A3 (en) Delivery of therapeutics
WO2009035959A3 (en) Radiofluorination methods
WO2011022393A3 (en) Phosphatidylcholine transfer protein inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07839556

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07839556

Country of ref document: EP

Kind code of ref document: A2